For the Inventor, By the Inventor

Enter assignee name

Lsi Medience Corporation

Calculating rank

USPTO Granted Patents = 27

% Expired Patents = 14.8

CIPO Patents = 1

EPO Patents = 27

Trademarks = 4

Forward Citations = 21

Loading Chart...

Loading Chart...

72 inventors (with patents filed for the assignee):

Yoshikazu Okamura (3 out of 5 patents)

Yuhang Yang (2 out of 2 patents)

Hiroshi Terasaki (2 out of 9 patents)

4. Mitsunobu Shimadzu (2 out of 2 patents)

5. Kenzo Fujimoto (2 out of 13 patents)

6. Shigeatsu Endo (2 out of 2 patents)

7. Kiyonori Katsuragi (2 out of 9 patents)

8. Shigeru Tashiro (2 out of 17 patents)

9. Suguru Akamatsu (2 out of 5 patents)

10. Keiichi Shoji (2 out of 3 patents)

11. Hideaki Onishi (2 out of 2 patents)

12. Midori Abe (2 out of 2 patents)

13. Toru Hadama (2 out of 2 patents)

14. Ayako Nishimura (2 out of 8 patents)

15. Mio Ooguchi (2 out of 2 patents)

Core Competencies:

Bladder Cancer

Thrombin Measurement

Cardiac Troponin

Cancer Cell Culture

Immunoassay

Polymer Microparticles

Infectious Coagulation

Monoclonal Antibodies

Nucleic Acid Amplification

Sepsis Prognosis

Animal Urinary Function

D-dimer Analysis

27 patents: Sort by Forward Citations

1. 12742781 - Diagnosis method for bladder cancer (2026-09-22),

2. 11873514 - Method of screening for a substance that acts on a cell mass (2024-01-16),

3. 11549100 - Three-dimensional culture of primary cancer cells using tumor tissue (2023-01-10),

4. 11422128 - Immunoassay employing sulfated polysaccharide (2022-08-23),

5. 11378577 - Reagent and method for measuring thrombin-antithrombin complex (2022-07-05),

6. 11237157 - Reagent and method for assaying thrombin-antithrombin complex (2022-02-01),

7. 11225683 - Photocoupling method using probe containing photoresponsive nucleic acids (2022-01-18),

8. 11125742 - Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit (2021-09-21),

9. 11041864 - Method for prediction of prognosis of sepsis (2021-06-22),

10. 10677695 - Magnetic material for collecting magnetic particles and utilization thereof (2020-06-09),

11. 10634681 - Method for measuring cardiac troponin (2020-04-28),

12. 10557848 - Polymer microparticle for carrying physiologically active substance and method for preparing same (2020-02-11),

13. 10191038 - Immunological measuring method and measuring kit for whole blood sample (2019-01-29),

14. 10168325 - Non-specific reaction inhibitor (2019-01-01),

15. 9944979 - Inhibition method of nucleic acid amplification by photoirradiation and method of selective nucleic acid amplification with high sensitivity (2018-04-17),

Company Overview

Lsi Medience Corporation is a prominent player in the healthcare sector, specializing in the development and manufacturing of advanced medical devices and diagnostic solutions. The company focuses on enhancing patient care through innovative technologies, particularly in the fields of in vitro diagnostics and medical imaging. Based in Tokyo, Japan, Lsi Medience is committed to improving healthcare outcomes by leveraging cutting-edge research and development, ensuring high-quality products that meet the evolving needs of the medical community.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

27 Patents

#1,138 in Tokyo

#2,459 in Japan

#24,046 in the World

Lsi Medience Corporation

Forward Citations = 21

72 inventors:

Yoshikazu Okamura (3 out of 5 patents)

Yuhang Yang (2 out of 2 patents)

Hiroshi Terasaki (2 out of 9 patents)

4. Mitsunobu Shimadzu (2 out of 2 patents)

5. Kenzo Fujimoto (2 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lsi Medience Corporation. Retrieved from https://idiyas.com/company/lsi-medience

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…